Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
德勤华永会计师事务所(特殊普通合伙)关于成都先导药物开发股份有限公司募集资金存放与实际使用情况的专项报告及审核报告
Regulatory Filings
2025-04-25 Chinese
2024年度独立董事述职报告（薛军福）
Regulatory Filings
2025-04-25 Chinese
成都先导药物开发股份有限公司2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "成都先导药物开发股份有限公司 2024 年年度报告摘要" which translates to "Chengdu Lead Drug Development Co., Ltd. 2024 Annual Report Summary." It contains detailed financial data for the year 2024, including total assets, net profit, revenue, and quarterly financial data. It also includes extensive business descriptions, risk factors, management discussion, and analysis of the company's operations and industry position. The document is about 15,000 characters long, which is substantial and contains actual financial statements and analysis, not just an announcement or summary. The presence of audited financial data and management discussion aligns with the characteristics of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K).
2025-04-25 Chinese
成都先导药物开发股份有限公司第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Chengdu Lead Drug Development Co., Ltd. It details the approval of various reports and proposals including the 2024 Annual Report, 2024 Annual Supervisory Board Work Report, 2024 Financial Final Report, 2024 Profit Distribution Plan, 2024 Internal Control Evaluation Report, 2025 Financial Budget Report, and others. The document states that these reports have been reviewed and approved by the Supervisory Board and will be submitted to the shareholders' meeting for further approval. The document itself does not contain the full reports or detailed financial statements but rather announces the resolutions and approvals of these reports. The document length is under 5,000 characters and it references that the full reports are published on the Shanghai Stock Exchange website. Therefore, this document is an announcement of the Supervisory Board meeting resolutions and approvals, not the reports themselves. This fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting resolutions and approvals without the full report content.
2025-04-25 Chinese
成都先导药物开发股份有限公司关于德勤华永会计师事务所（特殊普通合伙）履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of Deloitte Huayong Accounting Firm as the auditor for Chengdu Lead Drug Development Co., Ltd. for the fiscal year 2024. It details the auditor's qualifications, quality management system, audit procedures, independence, and compliance with regulatory requirements. The document does not contain actual financial statements or detailed financial data but rather assesses the auditor's role and performance in the audit process. It is a standalone audit-related report focusing on the auditor's duties and quality control, not the full annual report or financial statements. Therefore, it fits the category of an Audit Report / Information (AR). The document length is 4773 characters, which is sufficient to be a substantive report rather than a brief announcement. Hence, the classification is AR with high confidence.
2025-04-25 Chinese
成都先导药物开发股份有限公司关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of Chengdu Lead Drug Development Co., Ltd. It includes details such as the date, location, voting methods, agenda items to be discussed and voted on, and instructions for shareholders to attend and vote. The document does not contain the actual annual report or financial statements but rather the announcement and procedural information for the upcoming AGM. The document length is 3860 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.